Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: VIP · Vasoactive intestinal peptide
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Vasoactive peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
VIP-receptor signaling with vascular and immune effects.
Evidence and critical reading
Reported scientific and empirical uses
Respiratory function · Cardiovascular and vascular function
VIP/aviptadil is mentioned for lung, vasodilation and recovery; separate molecule, product and diagnosis.
Human evidence
TESICO randomized trial did not demonstrate day-90 benefit in COVID-associated hypoxemic respiratory failure; stopped for futility.
Preclinical evidence
Mechanistic lung protection cannot overturn a neutral clinical trial.
Critical reading and limitations
TESICO did not show clinical benefit and stopped for futility; registration is not efficacy evidence.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Hemodynamic and gastrointestinal effects matter; outcome and adverse-event interpretation must follow exact trial setting.
Hemodynamic/GI effects matter; the hospital study does not validate nonspecific home use.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID37348524 · Randomized controlled trial
COVID-19 respiratory failure; 461 treated.
Hospital IV.
No significant day-90 clinical benefit; futility.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 471
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Aviptadil · 9 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT05137795 · Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19Registry status: WithdrawnLast update posted: May 14, 2026Query verification: October 16, 2026
NCT04488081 · I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsRegistry status: Active, not recruitingLast update posted: March 16, 2026Query verification: October 16, 2026
NCT04843761 · ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19Registry status: CompletedLast update posted: October 24, 2025Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID37348524
Brown SM, Barkauskas CE, Grund B, Sharma S, Phillips AN, Leither L, Peltan ID, Lanspa M, Gilstrap DL, Mourad A, Lane K, Beitler JR, Serra AL, Garcia I, Almasri E, Fayed M, Hubel K, Harris ES, Middleton EA, Barrios MAG, Mathews KS, Goel NN, Acquah S, Mosier J, Hypes C, Salvagio Campbell E, Khan A, Hough CL, Wilson JG, Levitt JE, Duggal A, Dugar S, Goodwin AJ, Terry C, Chen P, Torbati S, Iyer N, Sandkovsky US, Johnson NJ, Robinson BRH, Matthay MA, Aggarwal NR, Douglas IS, Casey JD, Hache-Marliere M, Georges Youssef J, Nkemdirim W, Leshnower B, Awan O, Pannu S, O'Mahony DS, Manian P, Awori Hayanga JW, Wortmann GW, Tomazini BM, Miller RF, Jensen JU, Murray DD, Bickell NA, Zatakia J, Burris S, Higgs ES, Natarajan V, Dewar RL, Schechner A, Kang N, Arenas-Pinto A, Hudson F, Ginde AA, Self WH, Rogers AJ, Oldmixon CF, Morin H, Sanchez A, Weintrob AC, Cavalcanti AB, Davis-Karim A, Engen N, Denning E, Taylor Thompson B, Gelijns AC, Kan V, Davey VJ, Lundgren JD, Babiker AG, Neaton JD, Lane HC, ACTIV-3b/Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Study Group.
October 16, 2026
- R41
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026